ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Chiesi Farmaceutici and Viatris side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Chiesi FarmaceuticiViatris
studies on the registry299778
open to participants now379
phase 3 studies under way76
reach primary completion within a year118
programswith a study of their own in two years156

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseChiesi FarmaceuticiViatris
Phase 1

Chiesi Farmaceutici: 2 of its 15 programs at phase 1

  1. CHF10073phase 1
  2. CHF10136phase 1
13%
00%
Phase 2

Chiesi Farmaceutici: 2 of its 15 programs at phase 2

  1. CHF-6467phase 2
  2. CHF10067phase 2
13%

Viatris: 1 of its 6 programs at phase 2

  1. MR-130A-01phase 2
17%
Phase 3

Chiesi Farmaceutici: 6 of its 15 programs at phase 3

  1. florensocatibphase 3
  2. episalvanphase 3
  3. birch triterpenesphase 3
  4. CHF5993 100/6/12.5 μg pMDI HFA-152aphase 3
  5. Experimental: Participant Group CHF 5993 pMDI HFA-152aphase 3

and 1 more — sign in to see them all

40%

Viatris: 2 of its 6 programs at phase 3

  1. cenerimodphase 3
  2. selatogrelphase 3
33%
Approved, new studies

Chiesi Farmaceutici: 5 of its 15 programs at approved, new studies

  1. CHF5993approved, new study
  2. sebetralstatapproved, new study
  3. Foster® 200/6 pMDI (BDP/FF-200/6 µg)approved, new study
  4. Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation)approved, new study
  5. ff-200approved, new study
33%

Viatris: 3 of its 6 programs at approved, new studies

  1. Gabapentinapproved, new study
  2. Alprazolamapproved, new study
  3. Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionateapproved, new study
50%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Chiesi Farmaceutici4 readouts · 0 phase 3·

Chiesi Farmaceutici, Dec ’26: 1 program whose next study reaches primary completion

  1. florensocatibphase 3 · Dec 9 · NCT07683793
·

Chiesi Farmaceutici, Feb ’27: 1 program whose next study reaches primary completion

  1. CHF-6467phase 2 · Feb 28 · NCT07163182
···

Chiesi Farmaceutici, Jun ’27: 1 program whose next study reaches primary completion

  1. CHF5993approved, new study · Jun 3 · NCT07301736
·

Chiesi Farmaceutici, Aug ’27: 1 program whose next study reaches primary completion

  1. CHF10073phase 1 · Aug 0 · NCT07876284
··
Viatris4 readouts · 3 phase 3

Viatris, Nov ’26: 1 program whose next study reaches primary completion

  1. MR-130A-01phase 2 · Nov 30 · NCT07365904

Viatris, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cenerimodphase 3 · Dec 31 · NCT05672576

Viatris, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Gabapentinapproved, new study · Jan 31 · NCT07813026
·····

Viatris, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. selatogrelphase 3 · Jul 0 · NCT04957719
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Chiesi Farmaceutici

New programs 1

  • CHF10136phase 1 · first study · Sep 18 · Asthma

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Viatris

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionChiesi FarmaceuticiViatris
Asthmaboth · compare here

Viatris in Asthma: 1 program

  1. Alprazolamapproved, new study

Their studies: Viatris’s studies of Asthma in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Chiesi Farmaceutici 1 of 15 · Viatris 4 of 6 programs (5 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.